-
Mural Oncology (MURA) Halted, News Pending
-
Mural Oncology (MURA) PT Lowered to $4 at Raymond James
-
Mural Oncology (MURA) Announces Plans to Explore Strategic Alternatives
-
Mural Oncology (MURA) PT Lowered to $6 at H.C. Wainwright
-
Morgan Stanley Downgrades Mural Oncology (MURA) to Equalweight
-
Raymond James Downgrades Mural Oncology (MURA) to Outperform
-
Jones Trading Downgrades Mural Oncology (MURA) to Hold
-
Mural Oncology (MURA) Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA
-
Mural Oncology (MURA) Misses Q4 EPS by 201c
-
Jones Trading Starts Mural Oncology (MURA) at Buy
-
Mural Oncology plc (MURA) Tops Q3 EPS by 10c
-
Mural Oncology (MURA) Files $300M Mixed Shelf
-
H.C. Wainwright Starts Mural Oncology (MURA) at Buy
-
Raymond James Starts Mural Oncology (MURA) at Strong Buy
-
Mural Oncology (MURA) Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
-
Mural Oncology (MURA) Appoints George Golumbeski to its Board

